Skip to main content
SpringerLink
Log in

Stellenwert und Grenzen klassischer Neuroleptika in der Langzeittherapie schizophrener Erkrankungen

  • Conference paper
Therapie mit klassischen und neuen Neuroleptika

  • 33 Accesses

Zusammenfassung

Schizophrene Verläufe haben sich im Laufe der Dekaden im Sinne eines Syndromwandels mit Abnahme schwerer Erkrankungsformen und Zunahme unspezifischer und milderer Symptomatik verändert (Hogarty 1977). Parallel hierzu hat der Anteil sozial Geheilter zugenommen, ohne daß sichere Veränderungen in den Prävalenz- oder Inzidenzraten nachweisbar wären (Häfner u. Heiden 1986; Hare 1986; Strömgren 1987; Torrey 1987). In welchem Ausmaß an dieser Entwicklung veränderte soziokulturelle, ökonomische und therapeutische Bedingungen beteiligt sind, muß offen bleiben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Psychiatric Association (1997) Practice Guideline for the Treatment of Patients with Schizophrenia. Washington: APA

    Google Scholar 

  • Awad AG (1985) Prediction of response to neuroleptic drug therapy in schizophrenia. Can J Psychiatry 30:241–242

    PubMed  CAS  Google Scholar 

  • Barnes TRE, Milavic G, Curson DA, Platt SD (1983) Use of the social behavior assessment schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide vs fluphenazine. Soc Psychiat 18:193–199

    Article  CAS  Google Scholar 

  • Bellack AS, Mueser KT (1993) Psychosocial treatment in schizophrenia. Schizophr Bull 19:317–336

    PubMed  CAS  Google Scholar 

  • Bland RC (1982) Predicting the outcome in schizophrenia. Can J Psychiatry 27:52–62

    PubMed  CAS  Google Scholar 

  • Bleuler M (1972) Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten. Thieme, Stuttgart

    Google Scholar 

  • Bleuler M, Huber G, Gross G, Schüttler R (1976) Der langfristige Verlauf schizophrener Psychosen. Nervenarzt 47:477–481

    PubMed  CAS  Google Scholar 

  • Brown GW, Bone M, Dalison B, Wing JK (1966) Schizophrenia and social care. Oxford University Press, Oxford

    Google Scholar 

  • Carpenter WT, Heinrichs DW (1983) Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 9:533–542

    PubMed  Google Scholar 

  • Carpenter WT, Hanlon TE, Heinrichs DW, Summerfeit AT, Kirkpatrick B, Levine J, Buchanan RW (1990) Continuous vs targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147:1138–1148

    PubMed  Google Scholar 

  • Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11:440–452

    PubMed  Google Scholar 

  • Carpenter WT, Heinrichs DW, Hanlon TE (1987) A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 144:1466–1470

    PubMed  Google Scholar 

  • Carpenter WT, Stephens JH, Rey AC, Hanlon TE, Heinrichs DW (1982) Early intervention vs continuous pharmacotherapy of schizophrenia. Psychopharmacol Bull 18:21–23

    Google Scholar 

  • Chiles JA, Sterchi D, Hyde T, Herz MI (1989) Intermittent medication for schizophrenic outpatients: who is eligible? Schizophr Bull 15:117–121

    PubMed  CAS  Google Scholar 

  • Cheung HK (1981) Schizophrenics fully remitted on neuroleptics for 3 to 5 years — to stop or continue drugs? Br J Psychiatry 138:490–494

    Article  PubMed  CAS  Google Scholar 

  • Davis JM (1985) Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 11:18–21

    Google Scholar 

  • Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70–87

    PubMed  CAS  Google Scholar 

  • Frances A, Docherty JP, Kahn DA (1996) The expert consensus guidelines series. Treatment of schizophrenia. J Clin Psychiatry 57 (Suppl 12b): 1–58

    Google Scholar 

  • Freeman HL (1981) Long-term treatment of schizophrenia. Compr Psychiatry 22:94–102

    Article  PubMed  CAS  Google Scholar 

  • Gaebel W (1985) Gibt es differentielle Indikationen für verschiedene Neuroleptika? In: Linden M, Lipski C, Pietzcker A (Hrsg) Der schizophrene Patient in der Nervenarztpraxis. Thieme, Stuttgart New York, S 54–76

    Google Scholar 

  • Gaebel W (1992) Kombinationen von Psychopharmaka bei schizophrenen Erkrankungen. Münch Med Wschr 134:812–815

    Google Scholar 

  • Gaebel W (1993) Tardive Dyskinesien unter Neuroleptika-Behandlung. Dtsch Ärztebl 90:1041–1046

    Google Scholar 

  • Gaebel W (1994) Intermittent medication — an alternative? Acta Psychiatr Scand 89 (Suppl 382):33–38

    Article  Google Scholar 

  • Gaebel W (1996) Long-term treatment in schizophrenia: concept, methods, strategies. In: Häfner H, Wolpert E (Hrsg) New Research in psychiatry. Hogrefe & Huber, Seattle Toronto Bern Göttingen, pp 67–89

    Google Scholar 

  • Gaebel W, Awad AG (eds) (1994) Prediction of neuroleptic treatment outcome in schizophrenia — concepts and methods. Springer, Wien New York

    Google Scholar 

  • Gaebel W, Pietzcker A (1987) A prospective study of the course of illness in schizophrenic patients. Part II: Prediction of the outcome one year after clinic discharge. Schizophr Bull 13:299–306

    PubMed  CAS  Google Scholar 

  • Gaebel W, Pietzcker A, Poppenberg A (1981) Prädiktoren des Verlaufs schizophrener Erkrankungen unter neuroleptischer Langzeitmedikation. Pharmacopsychiatrie 14:180–188

    Article  CAS  Google Scholar 

  • Gaebel W, Frick U, Köpcke W et al. (1993) Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse. Br J Psychiatry 163 (Suppl 21): 8–12

    Google Scholar 

  • Gaebel W, Klimke A, Klieser E (1994) Kombination von Clozapin mit anderen Psychopharmaka. In: Naber D, Müller-Spahn F (Hrsg) Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer, Berlin Heidelberg New York Tokyo, S 43–58

    Google Scholar 

  • Glazer WM, Kane JM (1992) Depot neuroleptic therapy: An underutilized treatment option? J Clin Psychiatry 53:426–433

    PubMed  CAS  Google Scholar 

  • Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11:453–456

    PubMed  CAS  Google Scholar 

  • Goldberg SC, Schooler NR, Hogarty GE, Roper M (1977) Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Arch Gen Psychiatry 34:171–184

    Article  PubMed  CAS  Google Scholar 

  • Häfner H, Heiden van der W (1986) The contribution of European case registers to research on schizophrenia. Schizophr Bull 12:26–51

    PubMed  Google Scholar 

  • Hansell N, Willis GL (1977) Outpatient treatment of schizophrenia. Am J Psychiatry 134:1082–1086

    PubMed  CAS  Google Scholar 

  • Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A (1987a) The Vermont longitudinal study of persons with severe mental illness. I. Methodology, study sample, and overall status 32 years later. Am J Psychiatry 144:727–735

    PubMed  CAS  Google Scholar 

  • Harding CM, Zubin J, Strauss JS (1987b) Chronicity in schizophrenia: Fact, partial fact, or artifact? Hosp Comm Psychiat 38:477–486

    CAS  Google Scholar 

  • Hare E (1986) Aspects of the epidemiology of schizophrenia. Br J Psychiatry 149:554–561

    Article  PubMed  CAS  Google Scholar 

  • Harrow M, Grossmann LS (1984) Outcome in schizoaffective disorders: A critical review and reevaluation of the literature. Schizophr Bull 87–108

    Google Scholar 

  • Hartmann W, Kind J, Meyer JE, Müller P, Steuber H (1980) Neuroleptic drugs and the prevention of relapse in schizophrenia: A workshop report. Schizophr Bull 6:536–543

    PubMed  CAS  Google Scholar 

  • Heimann H (1983) Methodische Probleme der Wirksamkeitsprüfung von Neuroleptika im Rahmen der Langzeit-Therapie. In: Hippius H, Klein HE (Hrsg) Therapie mit Neuroleptika. Perimed, Bamberg

    Google Scholar 

  • Helmchen H (1978) Forschungsaufgaben bei psychiatrischer Langzeitmedikation. Nervenarzt 49:534–538

    PubMed  CAS  Google Scholar 

  • Herz MI, Melville Ch (1980) Relapse in schizophrenia. Am J Psychiatry 137:801–805

    PubMed  CAS  Google Scholar 

  • Herz MI, Szymanski HV, Simon JC (1982) Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry 139:918–922

    PubMed  CAS  Google Scholar 

  • Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, Mirza M et al. (1991) Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 48:333–339

    Article  PubMed  CAS  Google Scholar 

  • Hogarty GE (1977) Treatment and the course of schizophrenia. Schizophr Bull 3:587–599

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Ulrich RF (1977) Temporal effects of drug and placebo in delaying relapse in schizophrenia. Arch Gen Psychiatry 36:585–590

    Google Scholar 

  • Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF (1973) Drug and sociotherapy in the aftercare of schizophrenic patients. I. One-year relapse rates. Arch Gen Psychiatry 28:54–64

    Article  PubMed  CAS  Google Scholar 

  • Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 31:603–608

    Article  PubMed  CAS  Google Scholar 

  • Hogarty GE, Ulrich RF, Mussare F, Arishgueta N (1976) Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 37:494–500

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36:1283–1294

    Article  PubMed  CAS  Google Scholar 

  • Huber G, Gross G, Schüttler R (1979) Schizophrenie: Eine Verlaufs- und sozialpsychiatrische Langzeitstudie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Johnson DAW (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 45:13–21

    PubMed  CAS  Google Scholar 

  • Jolley AG, Hirsch SR, McRink A, Manchanda R (1989) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 298:985–990

    Article  PubMed  CAS  Google Scholar 

  • Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L (1990) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 301:837–842

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Marder SR (1993) Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287–302

    PubMed  CAS  Google Scholar 

  • Kane JM, Rifkin A, Quitkin F, Nayak D, Ramoslorenzi J (1982) Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 39:70–73

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Meltzer HY (1988) Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796

    Article  PubMed  CAS  Google Scholar 

  • Kissling W, Kane JM, Barnes TRE et al. (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: Towards a consensus view. In: Kissling W (ed) Guidelines for neuroleptic relapse prevention in schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 155–163

    Google Scholar 

  • König P (1992) Kontrolluntersuchungen bei neuroleptischer Therapie. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 4. Springer, Wien New York, S 127–130

    Google Scholar 

  • Lieberman JA (1993) Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 54 (Suppl 3):13–17

    PubMed  Google Scholar 

  • Marder SR, Hubbard JW, Van Putten T, Midha KK (1989) Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology 98:433–439

    Article  PubMed  CAS  Google Scholar 

  • Marder SR, Midha KK, Van Putten T et al. (1991) Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: Relationship to clinical response. Brit J Psychiatry 158:658–665

    Article  CAS  Google Scholar 

  • May PRA, Goldberg SC (1978) Prediction of schizophrenic patients’ response to pharmacotherapy. In: Lipton MA, Dimascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1139–1153

    Google Scholar 

  • May PRA, Tuma AH, Yale C, Potepan P, Dixon WJ (1976) Schizophrenia — a follow-up study of results of treatments. II. Hospital stay over two to five years. Arch Gen Psychiatry 33:481–506

    Article  PubMed  CAS  Google Scholar 

  • Möller HJ, Scharl W, Zerssen von D (1984) Strauss-Carpenter-Skala: Überprüfung ihres prognostischen Wertes für das 5-Jahres-„Outcome“ schizophrener Patienten. Eur Arch Psychiatr Clin Neurosci 234:112–117

    Google Scholar 

  • Pietzcker A (1985) A German multicenter study on the long-term treatment of schizophrenic outpatients. Pharmacopsychiatry 18:333–338

    Article  PubMed  CAS  Google Scholar 

  • Pietzcker A, Helmchen H (1983) Die Stellung der Neuroleptika im Gesamtbehandlungsplan schizophrener Psychosen. In: Hippius H, Klein HE (Hrsg) Therapie mit Neuroleptika. Perimed, Bamberg

    Google Scholar 

  • Pietzcker A, Gaebel W, Köpcke W et al. (1986) A German multicenter study on the neuroleptic long-term treatment of schizophrenic patients. Preliminary report. Pharmacopsychiatry 19:161–166

    Article  Google Scholar 

  • Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J (1993) Continuous vs intermittent neuroleptic longterm treatment in schizophrenia — results of a German multicenter study. J Psychiatr Res (im Druck)

    Google Scholar 

  • Rifkin A, Quitkin F, Rabiner CJ, Klein DF (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch Gen Psychiatry 34:43–47

    Article  PubMed  CAS  Google Scholar 

  • Schooler NR (1991) Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull 17:311–324

    PubMed  CAS  Google Scholar 

  • Schooler NR, Keith SJ, Severe JB, Matthews SM (1993) Treatment strategies in schizophrenia: effects of dosage reduction and family management on outcome. Schizophr Res 9:260

    Article  Google Scholar 

  • Stephens JH (1978) Long-term prognosis and follow-up in schizophrenia. Schizophr Bull 4:25–48

    PubMed  CAS  Google Scholar 

  • Strauss JS, Carpenter WT (1972) The prediction of outcome in schizophrenia. I. Characteristics of outcome. Arch Gen Psychiatry 27:739–746

    Article  PubMed  CAS  Google Scholar 

  • Strauss JS, Carpenter WT (1974) The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: A report from the WHO International Pilot Study of Schizophrenia. Arch Gen Psychiatry 31:37–42

    Article  PubMed  CAS  Google Scholar 

  • Strauss JS, Carpenter WT (1977) Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. Arch Gen Psychiatry 34:159–163

    Article  PubMed  CAS  Google Scholar 

  • Strauss JS, Carpenter WT, Bartko JJ (1974) The diagnosis and understanding of schizophrenia. Part III: Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 11:61–69

    PubMed  Google Scholar 

  • Strömgren E (1987) Changes in the incidence of schizophrenia? Br J Psychiatry 150:1–7

    Article  PubMed  Google Scholar 

  • Torrey EF (1987) Prevalence studies in schizophrenia. Br J Psychiatry 150:598–608

    Article  PubMed  CAS  Google Scholar 

  • Tsuang MT, Woolson RF, Fleming JA (1979) Long-term outcome of major psychoses. I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Arch Gen Psychiatry 39:1295–1301

    Article  Google Scholar 

  • Vaughn CE, Snyder KS, Jones S, Freeman WB, Falloon LRH (1984) Family factors in schizophrenic relapse: Replication in California of the British research on expressed emotion. Arch Gen Psychiatry 41:1169–1177

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization (WHO) (1979) Schizophrenia. An international follow-up study. J. Wiley & Son, Chichester New York Brisbane Toronto

    Google Scholar 

  • Wyatt RJ (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325–351

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. Gaebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Jänner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik, Georg-August-Universität, von-Siebold-Straße 5, 37075, Göttingen, Deutschland

    Borwin Bandelow  & Eckart Rüther  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Gaebel, W., Jänner, M. (1998). Stellenwert und Grenzen klassischer Neuroleptika in der Langzeittherapie schizophrener Erkrankungen. In: Bandelow, B., Rüther, E. (eds) Therapie mit klassischen und neuen Neuroleptika. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72152-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72152-6_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-64095-0

  • Online ISBN: 978-3-642-72152-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation